Interaction of Statins with Grapefruit Juice

Müge ATEŞ, (İnönü Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Malatya, Türkiye)
Selma SAHIN (Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Ankara, Türkiye)
FABAD Journal of Pharmaceutical Sciences
15 1
Yıl: 2023 Cilt: 48 Sayı: 2 Sayfa Aralığı: 337 - 358 Metin Dili: İngilizce DOI: 10.55262/fabadeczacilik.1187441 İndeks Tarihi: 17-08-2023

Interaction of Statins with Grapefruit Juice

Öz:
Grapefruit juice, which discovered to interact with felodipine for the first time, is now known to interact with more than 80 drugs. Statins are among the drugs that interact with grapefruit juice. Grapefruit juice-statin interactions were first investigated in 1998 in human pharmacokinetic studies with lovastatin and simvastatin. The pharmacokinetic and pharmacodynamic basis of the interaction has been extensively investigated in studies. Flavonoids and furanocoumarins, the main components of grapefruit juice, have been reported to cause drug interactions. Furthermore, statin-grapefruit juice interactions occur mostly through inhibition of cytochrome-3A4 (CYP3A4), to a lesser extent through inhibition of P-glycoprotein (Pgp) and organic anion transporting polypeptides (OATPs). Changes in plasma drug levels as a result of interaction may increase the side-effect of statins or reduce their therapeutic efficacy. Therefore, patients using statins are generally advised to avoid grapefruit juice consumption.
Anahtar Kelime: Grapefruit juice drug interaction statins CYP3A4 P-gp OATP

Statinlerin Greyfurt Suyu ile Etkileşimi

Öz:
İlk kez felodipin ile etkileştiği keşfedilen greyfurt suyunun günümüzde 80’den fazla ilaçla etkileştiği bilinmektedir. Statinler de greyfurt suyuyla etkileşen ilaçlar arasında yer almaktadır. Greyfurt suyu- statin etkileşimleri ilk olarak 1998 yılında lovastatin ve simvastatin ile insanlarda yapılan farmakokinetik çalışmalarla araştırılmıştır. Yapılan çalışmalarda etkileşimin farmakokinetik ve farmakodinamik temeli kapsamlı bir şekilde araştırılmıştır. Greyfurt suyunun ana bileşenleri olan flavonoidler ve furanokumarinlerin ilaç etkileşimlerine neden olduğu belirtilmiştir. Ayrıca, statin-greyfurt suyu etkileşimleri çoğunlukla sitokrom-3A4’ün (CYP3A4) inhibisyonu yoluyla, daha az oranda P-glikoprotein (P-gp) ve organik anyon taşıyıcı polipeptitlerinin (OATPler) inhibisyonu yoluyla meydana gelmektedir. Etkileşim sonucu plazma ilaç seviyelerindeki değişiklikler, statinlerin yan etkilerini artırabilir veya terapötik etkinliklerini azaltabilir. Bu nedenle statin kullanan hastaların genellikle greyfurt suyu tüketiminden uzak durmaları önerilmektedir.
Anahtar Kelime: Greyfurt suyu ilaç etkileşimi statinler CYP3A4 P-gp OATP

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Alakhali, K., Hassan, Y., Mohamed, N., Mordi, M.N. (2013). Pharmacokinetic of simvastatin study in Malaysian subjects. IOSR Journal of Pharmacy, 3(1), 46-51.
  • Amly, W., Karaman, R. (2015). Commonly used drugs uses, side effects, bioavailability and approaches to improve it. 1th ed. Nova Science Publishers, USA, 131-172.
  • Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K.I., Miyata, M., Yamazoe, Y., Takamura, T., Kane- ko, S., Fujimura, A. (2005). Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. British Journal of Clinical Phar- macology, 60(5), 494-497. doi: 10.1111/j.1365- 2125.2005.02462.x.
  • Azemavah, V., Movahed, M.R., Centuori, P., Penaflor, R., riel, P.L., Situ, S., Shadmehr, M., Hashemzadeh, M. (2019). State of the art comprehensive review of individual statins, their differences, pharma- cology, and clinical implications. Cardiovascular Drugs and Therapy, 33, 625-639. doi: https://doi. org/10.1007/s10557-019-06904-x.
  • Bailey, D.G., Spence, J.D., Edgar, B., Bayliff, C.D., Ar- nold, J.M. (1989). Ethanol enhances the hemody- namic effects of felodipine. Clinical and Investiga- tive Medicine, 12(6), 357-362.
  • Bailey, D.G., Kreeft, J.H., Munoz, C., Freeman, D.J., Bend, J.R. (1998). Grapefruit juice-felodipine in- teraction: Effect of naringin and 6’,7’-dihydroxy- bergamottin in humans. Clinical Pharmacology & Therapeutics, 64(3), 248-256. doi: https://doi. org/10.1016/S0009-9236(98)90173-4.
  • Bailey, D.G., Dresser, G.K. (2004). Interactions be- tween grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs, 4(5), 281-297. doi: https://doi.org/10.2165/00129784- 200404050-00002.
  • Bailey, D.G. (2010). Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British Journal of Clinical Pharmacology, 70(5), 645-655. doi: 10.1111/j.1365-2125.2010.03722.x
  • Bailey, D.G., Dresser, G., Arnold, M.O. (2013). Grape- fruit–medication interactions: Forbidden fruit or avoidable consequences? Canadian Medical Asso- ciation Journal, 185(4), 309-316. doi: https://doi. org/10.1503/cmaj.120951.
  • Bang, L.M., Goa, K.L. (2003). Pravastatin a review of its use in elderly patients. Drugs Aging, 20(14), 1061- 1082. doi: https://doi.org/10.2165/00002512- 200320140-00005.
  • Bellosta, S., Paoletti, R., Corsini, A. (2004). Safety of statins focus on clinical pharmacokinetics and drug Interactions. Circulation, 109(23), 50-57. doi: 10.1161/01.CIR.0000131519.15067.1f.
  • Bonsu, K.O., Kadirvelu, A., Reidpath, D.D. (2013). Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis. Systematic Reviews, 2(22), 1-7. doi: 10.1186/2046-4053-2-22.
  • Carella, A.M., Marinelli, T., Melfitano, A., Di Pum- po, M., Conte, M., Modola, G., Puntonio, M.C., Benvenuto, A. (2016). Focus on pitavastatin. International Journal of Cardiology and Lip- idology Research, 3, 11-19. doi: http://dx.doi. org/10.15379/2410-2822.2016.03.01.03
  • Carswell, C.I., Plosker, G.L., Jarvis, B. (2002). Rosu- vastatin. Drugs, 62(14). 2075-2085. doi: https:// doi.org/10.2165/00003495-200262140-00008.
  • Chen, M., Zhou, S.Y., Fabriaga, E., Zhang, P.H., Zhou, Q. (2018). Food-drug interactions precipitat- ed by fruit juices other than grapefruit juice: An update review. Journal of Food and Drug Anal- ysis, 26, S61-S71. doi: https://doi.org/10.1016/j. jfda.2018.01.009.
  • Costache, I.I., Miron, A., Hsncianu, M., Aursulesei, V., Dan Costache, A., Aprotosoaie, A.C. (2019). Pharmacokinetic interactions between cardiovas- cular medicines and plant products. Cardiovas- cular Therapeutics, 2019, 1-19. doi: https://doi. org/10.1155/2019/9402781.
  • Dahan, A., Altman, H. (2004). Food–drug interac- tion: grapefruit juice augments drug bioavailabil- ity mechanism, extent and relevance. European Journal of Clinical Nutrition, 58, 1-9. doi: 10.1038/ sj.ejcn.1601736.
  • Dahan, A., Amidon, G.L. (2009). Grapefruit juice and its constituents augment colchicine intestinal ab- sorption: Potential hazardous interaction and the role of P-glycoprotein. Pharmaceutical Research, 26(4), 883-892. doi: 10.1007/s11095-008-9789-7.
  • De Castro, W.V., Talcott, S.M., Rubner, A., Butter- weck, V., Derendorf, H. (2006). Variation of flavo- noids and furanocoumarins in grapefruit juices: A potential source of Variability in grapefruit Juice− Drug interaction studies. Journal of Agricultural and Food Chemistry, 54, 249-255. doi: https://doi. org/10.1021/jf0516944.
  • De Castro, W.V., Talcott, S.M., Derendorf, H., Butter- weck, V. (2007). Grapefruit juice–drug interac- tions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 Cells. Journal of Pharmaceu- tical Sciences, 96(10), 2808-2817. doi: 10.1002/ jps.20975.
  • Donovan, J.M., Kisicki, J.C., Stiles, M.R., Tracewell, W.G., Burke, S.K. (2002). Effect of colesevelam on lovastatin pharmacokinetics. The Annals of Pharmacotherapy, 36, 392-397. doi: https://doi. org/10.1345/aph.1A144.
  • Dresser, G.K., Bailey, D.G. (2003). The effects of fruit juices on drug disposition: a new model for drug interactions. European Journal of Clin- ical Investigation, 33(2), 10-16. doi: https://doi. org/10.1046/j.1365-2362.33.s2.2.x.
  • Duggan, S.T. (2012). Pitavastatin a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia. Drugs, 72(4), 565-584. doi: https://doi.org/10.2165/11207180-000000000- 00000.
  • Eagling, V.A., Profit, L., Back, D.J. (1999). Inhibi- tion of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV- 1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology, 48, 543-552. doi: 10.1046/j.1365- 2125.1999.00052.x.
  • Fukazawa, I., Uchida, N., Uchida, E., Yasuhara, H. (2003). Effects of grapefruit juice on pharmacoki- netics of atorvastatin and pravastatin in Japanese. British Journal of Clinical Pharmacology, 57(4), 448-455. doi: 10.1046/j.1365-2125.2003.02030.x.
  • Fukuda, K., Ohta, T., Oshima, Y., Ohashi, N., Yoshi- kawa, M., Yamazoe, Y. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin di- mers as components of drug interaction. Pharma- cogenetics, 7(5), 391-396. doi: 10.1097/00008571- 199710000-00008.
  • Fukuda, K., Guo, L., Ohashi, N., Yoshikawa, M., Yam- azoe, Y. (2000). Amounts and variation in grape- fruit juice of the main components causing grape- fruit–drug interaction. Journal of Chromatogra- phy B, 741, 195-203. doi: https://doi.org/10.1016/ S0378-4347(00)00104-3.
  • Gazzerro, P., Proto, M.C., Gangemi, G., Malfitano, A.M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., Bifulco, M. (2012). Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacological Reviews, 64, 102-146. doi: http://dx.doi.org/10.1124/pr.111.004994.
  • Goff-Klein, N.L., Klein, L., Herin, M., Koffel, J.C., Ubeaud, G. (2004). Inhibition of in-vitro simvas- tatin metabolism in rat liver microsomes by ber- gamottin, a component of grapefruit juice. Journal of Pharmacy and Pharmacology, 56, 1007-1014. doi: 10.1211/0022357044012.
  • Golomb, B.A., Evans, M.A. (2008). Statin adverse ef- fects a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs, 8(6), 373-418. doi: https:// doi.org/10.2165/0129784-200808060-00004.
  • Graeser, K.A., Strachan, C.J., Patterson, J.E., Gordon, K.C., Rades, T. (2008). Physicochemical proper- ties and stability of two differently prepared amor- phous forms of simvastatin. Crystal Growth & De- sign, 8(1), 128-135. doi: https://doi.org/10.1021/ cg700913m.
  • Greenblatt, D.J., Patki, K.C., von Moltke, L.L., Shad- er, R.I. (2001). Drug interactions with grapefruit juice: An update. Journal of Clinical Psychophar- macology, 21(4), 357-359.
  • Guo, L.Q., Yamazoe, Y. (2004). Inhibition of cyto- chrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacologica Sinica, 25(2), 129-136.
  • Hanley, M.J., Cancalon, P., Widmer, W.W., Greenblatt, D.J. (2011). The effect of grapefruit juice on drug disposition. Expert Opinion on Drug Metabolism & Toxicology, 7(3), 267-286. doi: https://doi.org/1 0.1517/17425255.2011.553189.
  • Hatanaka, T. (2000). Clinical pharmacokinetics of pravastatin mechanisms of pharmacokinetic events. Clinical Pharmacokinetics, 39(6), 397- 412. doi: https://doi.org/10.2165/00003088- 200039060-00002.
  • Hayashi, T., Yokote, K., Saito, Y., Iguchi, A. (2007). Pi- tavastatin: efficacy and safety in intensive lipid low- ering. Expert Opinion on Pharmacotherapy, 8(14), 2315-2327. doi: 10.1517/14656566.8.14.2315.
  • Ho, P.C., Saville, D.J. (2001). Inhibition of human CYP3A4 activity by grapefruit flavonoids, fu- ranocoumarins and related compounds. Journal of Pharmacy and Pharmaceutical Sciences, 4(3), 217-227.
  • Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y., Kim, R.B. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacoge- netics. Gastroenterology, 130(6), 1793-1806. doi: https://doi.org/10.1053/j.gastro.2006.02.034.
  • Hu, M., Mak, V.W.L., Chu, T.T.W., Waye, M.M.Y., Tom- linson, B. (2009). Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Current Pharmacog- enomics and Personalized Medicine, 7, 1-26. doi: https://doi.org/10.2174/187569209787582349.
  • Hu, M., Lun Mak, V.W., Yin, O.Q.P., Chu, T.T.W., Tomlinson, B. (2013). Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab- olism and Pharmacokinetics, 28(2), 104-108. doi: https://doi.org/10.2133/dmpk.DMPK-12- RG-067.
  • Hung, W.L., Suh, J.H., Wang, Y. (2017). Chemistry and health effects of furanocoumarins in grapefruit. Journal of Food and Drug Analysis, 25, 71-83. doi: http://dx.doi.org/10.1016/j.jfda.2016.11.008.
  • Igual, M., Martinez, E.G., Camacho, M.M., Navar- rete, N.M. (2011). Changes in flavonoid content of grapefruit juice caused by thermal treatment and storage. Innovative Food Science and Emerg- ing Techologies, 12, 153-162. doi: 10.1016/j.if- set.2010.12.010.
  • Kafle, A., Mohapatra, S.S., Sarma, J., Reddy, I. (2018). Food-drug interaction: A review. The Pharma In- novation Journal, 7(1), 114-118.
  • Kajinami, K., Takekoshi, N., Saito, Y. (2003). Pitavas- tatin: Efficacy and safety profiles of A novel syn- thetic HMG-CoA reductase inhibitor. Cardiovas- cular Drug Reviews, 21(3), 199-215. doi: https:// doi.org/10.1111/j.1527-3466.2003.tb00116.x.
  • Kantola, T., Kivistö, K.T., Neuvonen, P.J. (1998). Grapefruit juice greatly increases serum concen- trations of lovastatin and lovastatin acid. Clinical Pharmacology & Therapeutics, 63(4), 397-402. doi: https://doi.org/10.1016/S0009-9236(98)90034-0.
  • Kellick, K.A., Bottorff, M., Toth, P.P. (2014). A clini- cian’s guide to statin drug-drug interactions. Jour- nal of Clinical Lipidology, 8, 30-46. doi: https:// doi.org/10.1016/j.jacl.2014.02.010.
  • Khan, F.N., Dehghan, M.H.G. (2011). Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. AAPS PharmSciTech, 12(4), 1077-1086. doi: https://doi. org/10.1208/s12249-011-9673-3.
  • Khan, S.I., Saha, S.K., Poddar, S.K., Bachar, R., Al Shoyaib, A., Chakrabarty, J.K., Promite, S., Bachar, S.C., Pal, T.K. (2017). Bioequivalence studies and pharmacokinetic properties of atorvastatin 40 mg tablet in healthy Bengali subjects. MOJ Bioequiv- alence & Bioavailability, 4(2), 1-7. doi: 10.15406/ mojbb.2017.04.00064.
  • Kiani, J., Imam, S.Z. (2007). Medicinal importance of grapefruit juice and its interaction with var- ious drugs. Nutrition Journal, 6(33), 1-9. doi: 10.1186/1475-2891-6-33.
  • Kim, J.S., Kim, M.S., Park, H.J., Jin, S.J., Lee, S., Hwang, S.J. (2008). Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS pro- cess. International Journal of Pharmaceutics, 359, 211-219. doi: 10.1016/j.ijpharm.2008.04.006.
  • Kong, R., Zhu, X., Meteleva, E.S., Chistyachenko, Y.S., Suntsova, L.P., Polyakov, N.E., Khvostov, M.V., Baev, D.S., Tolstikova, T.G., Yu, J., Dushkin, A.V., Su, W. (2017). Enhanced solubility and bio- availability of simvastatin by mechanochemical- ly obtained complexes. International Journal of Pharmaceutics, 534, 108-118. doi: http://dx.doi. org/10.1016/j.ijpharm.2017.10.011.
  • Kumar, N., Chaurasia, S., Patel, R.R., Khan, G., Kumar, V., Mishra, B. (2017). Atorvastatin calcium encap- sulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. Pharma- ceutical Development and Technology, 22(2), 156- 167. doi: 10.3109/10837450.2015.1108983.
  • Lada, M.K.,Baba, K., Dolatowski, F., Dobrowolska, A., Rakicka, M. (2018). The polymorphism of statins and its effect on their physicochemical properties. Polymers in Medicine, 48(2), 77-82. doi: 10.17219/ pim/102978.
  • Langtry, H.D., Markham, A. (1999). Fluvastatin a review of its use in lipid disorders. Drugs, 57(4), 583-606.
  • Law, M.R., Wald, N.J., Rudnicka, A.R. (2003). Quan- tifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. British Med- ical Journal, 326, 1-7. doi: https://doi.org/10.1136/ bmj.326.7404.1423.
  • Lee, J.W., Morris, J.K., Wald, N.J. (2016). Grapefruit juice and statins. The American Journal of Med- icine, 129, 26-29. doi: http://dx.doi.org/10.1016/j. amjmed.2015.07.036.
  • Lennernas, H. (2003). Clinical pharmacokinetics of atorvastatin. Clinical Pharmacokinetics, 42(13), 1141-1160.doi:https://doi.org/10.2165/00003088- 200342130-00005.
  • Lilja, J.J., Kivistö, K.T., Backman, J.T., Lamberg, T.S., Neuvonen, P.J. (1998). Grapefruit juice substan- tially increases plasma concentrations of bus- pirone. Clinical Pharmacology & Therapeutics, 64(6), 655-660. doi: https://doi.org/10.1016/ S0009-9236(98)90056-X.
  • Lilja, J.J., Kivistö, K.T., Neuvonen, P.J. (1999). Grape- fruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical Pharmacology & Therapeutics, 66(2), 118-127. doi: https://doi.org/10.1053/cp.1999. v66.100453001.
  • Lilja, J.J., Kivistö, K.T., Neuvonen, P.J. (2000). Dura- tion of effect of grapefruit juice on the pharma- cokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology & Therapeutics, 68(4), 384-390. doi: 10.1067/mcp.2000.110216.
  • Lilja, J.J., Neuvonen, M., Neuvonen, P.J. (2004). Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. British Jour- nal of Clinical Pharmacology, 58(1), 56-60. doi: 10.1111/j.1365-2125.2004.02095.x.
  • Mauro, V.F. (1993). Clinical pharmacokinetics and practical applications of simvastatin. Clinical Pharmacokinetics, 24(3), 195-202. doi: https:// doi.org/10.2165/00003088-199324030-00002.
  • McKenney, J. (2003). Pharmacologic characteristics of statins. Clinical Cardiology, 26, 32-38. doi: https:// doi.org/10.1002/clc.4960261507.
  • Melough, M.M., Chun, O.K. (2018). Dietary furo- coumarins and skin cancer: A review of current biological evidence. Food and Chemical Toxicol- ogy, 122, 163-171. doi: https://doi.org/10.1016/j. fct.2018.10.027.
  • Mouly, S., Linares, C.L., Sellier, P.O., Sene, D., Berg- mann, J.F. (2017). Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John’s Wort? Pharma- cological Research, 118, 82-92. doi: http://dx.doi. org/10.1016/j.phrs.2016.09.038.
  • Murphy, C., Deplazes, E., Cranfield, C.G., Garcia, A. (2020). The role of structure and biophysical properties in the pleiotropic effects of statins. In- ternational Journal of Molecular Sciences, 2020, 21(8745), 1-29. doi: 10.3390/ijms21228745.
  • Neuvonen, P.J., Backman, J.T., Niemi, M. (2008). Phar- macokinetic comparison of the potential over-the- counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clinical Pharmacokinetics, 47(7), 463-474. doi: https://doi.org/10.2165/00003088- 200847070-00003.
  • Ohta, T., Maruyama, T., Nagahashi, M., Miyamoto, Y., Hosoi, S., Kiuchi, F., Yamazoe, Y., Tsukamoto, S. (2002). Paradisin C: a new CYP3A4 inhibitor from grapefruit juice. Tetrahedron, 58, 6631-6635. doi: https://doi.org/10.1016/S0040-4020(02)00739-1.
  • Paine, M.F., Criss, A.B., Watkins, P.B. (2004). Two major grapefruit juice components differ in in- testinal CYP3A4 inhibition kinetic and bind- ing properties. Drug Metabolism and Dis- position, 32(10), 1146-1153. doi: https://doi. org/10.1124/dmd.104.000547.
  • Paine, M.F., Widmer, W.W., Hart, H.L., Pusek, S.N., Beavers, K.L., Criss, A.B., Brown, S.S., Thomas, B.F., Watkins, P.B. (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine in- teraction. The American Journal of Clinical Nutri- tion, 83, 1097-1105. doi: https://doi.org/10.1093/ ajcn/83.5.1097.
  • Pirmohamed, M. (2013). Drug-grapefruit juice inter- actions: two mechanisms are clear but individual responses vary. British Medical Journal, 346, 1-3. doi: https://doi.org/10.1136/bmj.f1.
  • Plosker, G.L., Wagstaff, A.J. (1996). Fluvastatin a review of its pharmacology and use in the man- agement of hypercholesterolaemia. Drugs, 51(3), 433-459. doi: https://doi.org/10.2165/00003495- 199651030-00011.
  • Quion, J.A.V., Jones, P.H. (1994). Clinical phar- macokinetics of pravastatin. Clinical Phar- macokinetics, 27(2), 94-103. doi: https://doi. org/10.2165/00003088-199427020-00002.
  • Rebello, S., Zhao, S., Hariry, S., Dahlke, M., Alexan- der, N., Vapurcuyan, A., Hanna, I., Jarugula, V. (2012). Intestinal OATP1A2 inhibition as a po- tential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. European Journal of Clinical Pharmacology, 68, 697-708. doi: 10.1007/s00228-011-1167-4.
  • Reddy, P., Ellington, D., Zhu, Y., Zdrojewski, I., Par- ent, S.J., Harmatz, J.S., Derendorf, H., Greenblatt, D.J., Browne, K. (2011). Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. British Journal of Clinical Pharmacology, 72(3), 434-441. doi: 10.1111/j.1365-2125.2011.03996.x.
  • Rogers, J.D., Zhao, J., Liu, L., Amin, R.D., Gagliano, K.D., Porras, A.G., Blum, R.A., Wilson, M.F., Ste- panavage, M., Vega, J.M. (1999). Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clinical Phar- macology & Therapeutics, 66(4), 358-366. doi: https://doi.org/10.1053/cp.1999.v66.a101208.
  • Ross, S.A., Ziska, D.S., Zhaod, K., ElSohly, M.A. (2000). Variance of common flavonoids by brand of grapefruit juice. Fitoterapia, 71, 154-161. doi: https://doi.org/10.1016/S0367-326X(99)00131-8.
  • Row, E.C., Brown, S.A., Stachulski, A.V., Lennard, M.S. (2006). Design, synthesis and evaluation of furanocoumarin monomers as inhibitors of CY- P3A4. Organic and Biomolecular Chemistry, 4, 1604-1610. doi: 10.1039/b601096b.
  • Saito, Y. (2011). Pitavastatin: An overview. Athero- sclerosis Supplements, 12(3), 271-276. doi: https:// doi.org/10.1016/S1567-5688(11)70886-8.
  • Schachter, M. (2004). Chemical, pharmacokinetic and pharmacodynamic properties of statins: an up- date. Fundamental & Clinical Pharmacology, 19, 117-125. doi: 10.1111/j.1472-8206.2004.00299.x.
  • Schmidt, L.E., Dalhoff, K. (2002). Food-drug interac- tions. Drugs, 62(10), 1481-1502. doi: https://doi. org/10.2165/00003495-200262100-00005.
  • Scott, L.J., Curran, M.P., Figgitt, D.P. (2004). Rosu- vastatin a review of its use in the management of dyslipidemia. American Journal of Cardio- vascular Drugs, 4(2), 117-138. doi: https://doi. org/10.2165/00129784-200404020-00005.
  • Scripture, C.D., Pieper, J.A. (2001). Clinical phar- macokinetics of fluvastatin. Clinical Pharma- cokinetics, 40(4), 263-281. doi: https://doi. org/10.2165/00003088-200140040-00003.
  • Sharannavar, B.R., Gadad, A.P. (2018). Physicochemi- cal characterization and dissolution study of spray dried amorphous lovastatin with polyvinylpyrro- lidone K30. The Pharma Innovation Journal, 7(3), 498-502.
  • Shayanfar, A., Ghavimi, H., Hamishehkar, H., Jouy- ban, A. (2013). Coamorphous atorvastatin calci- um to improve its physicochemical and pharma- cokinetic properties. The Journal of Pharmacy and Pharmaceutical Sciences, 16(4), 577-587. doi: https://doi.org/10.18433/J3XS4S.
  • Shirasaka, Y., Suzuki, K., Nakanishi, T., Tamai, I. (2010) Intestinal absorption of HMG-CoA re- ductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharmaceutical Research, 27, 2141-2149. doi: 10.1007/s11095- 010-0216-5.
  • Shirasaka, Y., Suzuki, K., Shichiri, M., Nakanishi, T., Tamai, I. (2010). Intestinal absorption of HMG- CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and p-glycoprotein/multidrug resistance 1. Drug Me- tabolism and Pharmacokinetics, 26(2), 171-179. doi: 10.2133/dmpk.DMPK-10-RG-073.
  • Shirasaka, Y., Suzuki, K., Nakanishi, T., Tamai, I. (2011). Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or p-glycoprotein. Journal of Pharmaceutical Scienc- es, 100(9), 3843-3853. doi: 10.1002/jps.22586.
  • Shirasaka, Y., Shichiri, M., Mori, T., Nakanishi, T., Ta- mai, I. (2013). Major active components in grape- fruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. Journal of Pharmaceutical Sciences, 102(1), 280-288.
  • Sicari, V., Pellicano, T.M., Giuffre, A.M., Zappia, C., Capocasale, M., Poiana, M. (2018). Physical chemical properties and antioxidant capacities of grapefruit juice (citrus paradisi) extracted from two different varieties. International Food Re- search Journal, 25(5), 1978-1984. doi: https://doi. org/10.1002/jps.23357.
  • Sirtori, C.R. (2014). The pharmacology of statins. Pharmacological Research, 88(2014), 3-11. doi: http://dx.doi.org/10.1016/j.phrs.2014.03.002.
  • Spence, D.J., Dresser, G.K. (2016). Overcoming chal- lenges with statin therapy. Journal of the Amer- ican Heart Association, 5(1), 1-13. doi: 10.1161/ JAHA.115.002497.
  • Srinivas, C., Sagar, S.V. (2012). Enhancing the bio- availability of simvastatin using microemulsion drug delivery system. Asian Journal of Pharma- ceutical and Clinical Research, 5(4), 134-139.
  • Stancu, C., Sima, A. (2001). Statins: mechanism of action and effects. Journal of Cellular and Mo- lecular Medicine, 5(4), 378-387. doi: https://doi. org/10.1111/j.1582-4934.2001.tb00172.x.
  • Tassaneeyakul, W., Guo, L.Q., Fukuda, K., Ohta, T., Yamazoe, Y. (2000). Inhibition selectivity of grape- fruit juice components on human cytochromes P450. Archives of Biochemistry and Biophysics, 378(2), 356-363. doi: https://doi.org/10.1006/ abbi.2000.1835.
  • Vanamala, J., Reddivari, L., Yoo, K.S., Pike, L.M., Pa- til, B.S. (2006). Variation in the content of bio- active flavonoids in different brands of orange and grapefruit juices. Journal of Food Compo- sition and Analysis, 19, 157-166. doi: 10.1016/j. jfca.2005.06.002.
  • Varma, M.V., Gardner, I., Steyn, S.J., Nkansah, P., Rot- ter, C.J., Pickett, C.W., Zhang, H., Di, L., Cram, M, Fenner, K.S., El-Kattan, A.F. (2012). pH-depen- dent solubility and permeability criteria for pro- visional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Molecular Phar- maceutics, 9, 1199-1212. doi: dx.doi.org/10.1021/ mp2004912.
  • Veronese, M.L., Gillen, L.P., Burke, J.P., Dorval, E.P., Hauck, W.W.,Pequignot, E., Waldman, S.A., Green- berg, H.E. (2003). Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grape- fruit juice. The Journal of Clinical Pharmacology, 43, 831-839. doi: 10.1177/0091270003256059.
  • White, C.M. (2002). A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. The Journal of Clinical Pharmacology, 42, 963-970. doi: https://doi.org/10.1177/009127000204200902.
  • Williams, D., Feely, J. (2002). Pharmacokinet- ic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Phar- macokinetics, 41(5), 343-370. doi: https://doi. org/10.2165/00003088-200241050-00003.
  • Zhang, J. (2007). Flavonoids in grapefruit and com- mercial grapefruit juices: concentration, distribu- tion, and potential health benefits. Proceedings of the Florida State Horticultural Society, 120, 288- 294.
  • Zhou, J., Zhou, D. (2015). Improvement of oral bio- availability of lovastatin by using nanostruc- tured lipid carriers. Drug Design, Development and Therapy, 9, 5269-5275. doi: https://doi. org/10.2147/DDDT.S90016.
  • Zolkiflee, N.F., Affandi, M.M., Majeed, A.B.A. (2017). Lovastatin: history, physicochemistry, pharma- cokinetics and enhanced solubility. International Journal of Research in Pharmaceutical Sciences, 8(1), 90-102.
APA Ateş M, Sahin S (2023). Interaction of Statins with Grapefruit Juice. , 337 - 358. 10.55262/fabadeczacilik.1187441
Chicago Ateş Müge,Sahin Selma Interaction of Statins with Grapefruit Juice. (2023): 337 - 358. 10.55262/fabadeczacilik.1187441
MLA Ateş Müge,Sahin Selma Interaction of Statins with Grapefruit Juice. , 2023, ss.337 - 358. 10.55262/fabadeczacilik.1187441
AMA Ateş M,Sahin S Interaction of Statins with Grapefruit Juice. . 2023; 337 - 358. 10.55262/fabadeczacilik.1187441
Vancouver Ateş M,Sahin S Interaction of Statins with Grapefruit Juice. . 2023; 337 - 358. 10.55262/fabadeczacilik.1187441
IEEE Ateş M,Sahin S "Interaction of Statins with Grapefruit Juice." , ss.337 - 358, 2023. 10.55262/fabadeczacilik.1187441
ISNAD Ateş, Müge - Sahin, Selma. "Interaction of Statins with Grapefruit Juice". (2023), 337-358. https://doi.org/10.55262/fabadeczacilik.1187441
APA Ateş M, Sahin S (2023). Interaction of Statins with Grapefruit Juice. FABAD Journal of Pharmaceutical Sciences, 48(2), 337 - 358. 10.55262/fabadeczacilik.1187441
Chicago Ateş Müge,Sahin Selma Interaction of Statins with Grapefruit Juice. FABAD Journal of Pharmaceutical Sciences 48, no.2 (2023): 337 - 358. 10.55262/fabadeczacilik.1187441
MLA Ateş Müge,Sahin Selma Interaction of Statins with Grapefruit Juice. FABAD Journal of Pharmaceutical Sciences, vol.48, no.2, 2023, ss.337 - 358. 10.55262/fabadeczacilik.1187441
AMA Ateş M,Sahin S Interaction of Statins with Grapefruit Juice. FABAD Journal of Pharmaceutical Sciences. 2023; 48(2): 337 - 358. 10.55262/fabadeczacilik.1187441
Vancouver Ateş M,Sahin S Interaction of Statins with Grapefruit Juice. FABAD Journal of Pharmaceutical Sciences. 2023; 48(2): 337 - 358. 10.55262/fabadeczacilik.1187441
IEEE Ateş M,Sahin S "Interaction of Statins with Grapefruit Juice." FABAD Journal of Pharmaceutical Sciences, 48, ss.337 - 358, 2023. 10.55262/fabadeczacilik.1187441
ISNAD Ateş, Müge - Sahin, Selma. "Interaction of Statins with Grapefruit Juice". FABAD Journal of Pharmaceutical Sciences 48/2 (2023), 337-358. https://doi.org/10.55262/fabadeczacilik.1187441
Sayfa Oluşturulma Tarihi
24-04-2024 8:51

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları